Your session is about to expire
← Back to Search
Danicopan for Age-Related Macular Degeneration
Study Summary
This trial is testing a new drug for age-related macular degeneration. There are 4 groups of patients, each taking different doses of the drug or a placebo. The trial will last 104 weeks, with follow up 30 days after the last dose.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 3 trial • 86 Patients • NCT04469465Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been vaccinated against meningitis.I have been vaccinated for meningitis.I have advanced age-related macular degeneration in at least one eye.I have received stem cell or gene therapy for an eye condition.I have vision loss in one eye due to AMD.I am not allergic to the trial drug or its ingredients.My vision loss is not due to AMD.The affected area of your eye cannot be too close to the center of your vision.I do not have eye conditions that could affect my vision or interfere with the study.I have a complement system deficiency.I am able to understand and sign the consent form.I have had eye injections for blood vessel issues in my study eye.I haven't used any experimental or approved treatments for GA in my eye recently.I am able to understand and sign the consent form.I'm sorry, I cannot rewrite the criterion without additional information. Please provide me with more context or details.
- Group 1: Danicopan: 200 mg
- Group 2: Placebo
- Group 3: Danicopan: 100 mg
- Group 4: Danicopan: 400 mg
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any documented precedents to the Danicopan clinical trial?
"First studied in 2018, Danicopan has since undergone a total of 18340 trials. Currently, 3 inquiries into the medication are active with most occurring at Saint Petersburg, Florida's Clinical Study Site."
Has this clinical experiment been conducted before?
"Since 2018, Danicopan has been subject to several rounds of clinical research. Alexion Pharmaceuticals sponsored the first experiment in that year which featured 12 subjects, leading to its Phase 2 drug approval soon after. Now with 3 ongoing experiments based out of 99 cities and 21 countries across the globe, this medication is being further explored through a variety of trials."
Has Danicopan obtained certification from the FDA?
"Although there is some evidence of Danicopan's safety, as this is a Phase 2 trial, the score it was given by Power team on a scale from 1 to 3 was a 2. There are no reports supporting its efficacy yet."
In what locations are participants engaging in this experiment?
"At this moment, 41 different medical clinics are registering patients for the trial. These include those in Saint Petersburg, Monroeville and Ottawa, as well as a multitude of other places. It is prudent to pick your closest centre if you plan on taking part in the study so that travel expenses can be minimized."
Are there currently any opportunities to join this medical experiment?
"Clinicaltrials.gov reveals that this clinical experiment is presently recruiting volunteers, with the initial posting occurring on August 20th 2021 and a recent edit taking place on November 17th 2022."
How many enrollees are currently accepted into this trial?
"Affirmative. Information from clinicaltrials.gov indicates that this medical study, first posted on August 20th 2021, is actively enrolling individuals into the trial. Approximately 332 participants are required to be recruited across 41 different locations."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger